ECHELON-2, (NCT01777152), 5-year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin plus CHP vs CHOP in patients with CD30-positive peripheral T-cell lyphoma Truemper, L., O'Connor, O. A., Pro, B., Illidge, T., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Menne, T., Belada, D., Illes, A., Tobinai, K., Tsukasaki, K., Yeh, S. P., Huettmann, A., Savage, K. J., Yuen, S., Iyer, S., Zinzani, P. L., Miao, H., Bunn, Fenton, K., Fanale, M., Puhlmann, M., Horwitz, S. KARGER. 2021: 128

View details for Web of Science ID 000760622600234